Status:
COMPLETED
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
Eligibility Criteria
Inclusion
- Confirmed locally advanced or metastatic NSCLC
- Failure of at least one but not more than two prior chemotherapy regimens
Exclusion
- Prior treatment with erlotinib (Tarceva), gefitinib (IRESSA), sunitinib (Sutent), sorafenib (Nexavar)
- Chemotherapy or other type of anti cancer therapy within 4 weeks of study start
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
1574 Patients enrolled
Trial Details
Trial ID
NCT00364351
Start Date
August 1 2006
End Date
November 1 2016
Last Update
January 25 2018
Active Locations (153)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berkeley, California, United States
2
Research Site
Los Angeles, California, United States
3
Research Site
Santa Rosa, California, United States
4
Research Site
Boynton Beach, Florida, United States